摘要
目的探讨Ⅱ期非小细胞肺癌(NSCLC)中Ⅲ型β微管蛋白(β-tubulin-Ⅲ)mRNA表达与诺维本+顺铂(NP)方案化疗敏感度的关系。方法单基因定量法检测已手术Ⅱ期NSCLC患者肿瘤组织中β-tubulin-ⅢmRNA表达,所有患者行NP方案化疗,并随访患者的无瘤生存时间(DFS)和总体生存率(OS),统计学分析β-tubulin-ⅢmRNA表达水平与患者DFS和OS的关系。结果 73例患者的OS与β-tubulin-Ⅲ的表达有关(P<0.01),患者的DFS与β-tubulin-Ⅲ的表达及淋巴结转移情况有关(P<0.01)。β-tubulin-Ⅲ低表达者的OS、DFS均高于β-tubulin-Ⅲ高表达者(P<0.05)。结论Ⅱ期NSCLC患者肿瘤组织中β-tubulin-Ⅲ表达水平可能是预测患者预后及化疗敏感度的一个指标,为选择合适化疗药物提供参考。
Objective To explore the relationship between chemotherapy sensitivity and the expression level of β-tubulin-ⅢrnRNA in patients with stage β NSCLC. Methods The expression of tubulin-ⅢmRNA was measured by Quanti-Gene assay. All patients accepted NP chemotherapy, and disease-free survival time （DFS） and overall survival time （OS） was analyzed. Results The OS of patients was relat ed with the expression level of -tubulin-[lI （P〈0. 01）, the DFS was related with the expression level of β-tubulin Ⅲ and lymph node metastasis （P〈0. 01 ）. The OS and DFS in patients with lower-expression level of β-tubulin-Ⅲ were longer than those with over-expression （P〈0. 05）. Conclusion The expression of β tubulin-Ⅲ in patients with stage Ⅲ NSCLC might be a predictive factor for chemotherapy sensitivity and the prognosis,and a reference for agents choose.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2013年第6期568-571,共4页
Cancer Research on Prevention and Treatment
基金
浙江省教育厅基金资助课题(2007-01345)
